Browse by author
Lookup NU author(s): Professor Johannes Attems
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
BRCA1/2 mutations predispose to early onset breast and ovarian cancers. The phenotypic expression of mutant alleles, however, is thought to be modified by factors that are also involved in the pathogenesis of sporadic breast cancer. One such protein is IGF-I, one of the strongest mitogens to breast cancer cells in vitro. We have utilized immunohistochemistry to compare the intratumoral IGF-I and IGF-I receptor (IGF-IR) protein expression in 57 BRCA1/2 mutation carriers and 102 matched breast cancer patients without a family history in a nested case-control study. BRCA1 silencing by siRNA was used to investigate the effect of BRCA mutations on IGF-I protein expression. IGF-I protein expression was detected in tumoral epithelium and surrounding stroma, and was significantly upregulated in tumors of BRCA mutation carriers when compared with matched sporadic tumors (epithelial: 87.7% vs 61.8%, P=0.001; stromal: 73.7% vs 34.3%, P
Author(s): Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Kostler WJ, Attems J, Mueller R, Blaukopf C, Kubista E, Hengstschlager M, Singer CF
Publication type: Article
Publication status: Published
Journal: Endocrine-Related Cancer
Year: 2007
Volume: 14
Issue: 4
Pages: 1053-1062
ISSN (print): 1351-0088
ISSN (electronic): 1479-6821
Publisher: Society for Endocrinology
URL: http://dx.doi.org/10.1677/ERC-06-0075
DOI: 10.1677/ERC-06-0075
Altmetrics provided by Altmetric
